Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia
Neuropsychiatric Disease and Treatment · 2023-05 · Volume 19 · 1145-1151
DOI: 10.2147/ndt.s406371 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuropsychiatric Disease and Treatment, 2023-05. Verfasst von Neil Kidambi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Mood Disorders Research Program, Depression Center, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Lo…. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mood Disorders Research Program, Depression Center, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, 40202, USA.
ORCID-Profile: Rif S El-Mallakh
Zitieren
APA
Kidambi, N., Elsayed, O. H., & El-Mallakh, R. S. (2023). Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia. Neuropsychiatric Disease and Treatment, Volume 19, 1145-1151. https://doi.org/10.2147/ndt.s406371
Vancouver
Kidambi N, Elsayed OH, El-Mallakh RS. Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia. Neuropsychiatric Disease and Treatment. 2023;Volume 19:1145-1151. doi:10.2147/ndt.s406371
BibTeX
@article{Kidambi2023,
author = {Kidambi, Neil and Elsayed, Omar H and El-Mallakh, Rif S},
title = {Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia},
journal = {Neuropsychiatric Disease and Treatment},
year = {2023},
volume = {Volume 19},
pages = {1145--1151},
doi = {10.2147/ndt.s406371}
}
EUVIMED